Takeda appoints David Henderson as Franchise Director, Specialty for Oceania
October 25, 2025
Takeda Australia
Australia
At Takeda, our purpose is clear: to create better health for people and a brighter future for the world. We focus on the highest unmet need, both in rare and more prevalent conditions, to deliver high quality medicines to patients as quickly as possible.
Our Commitment in Australia
We’re focused on accelerating access and tackling healthcare challenges so that Australians can get the medicines they need as quickly as possible. Our local partnerships reflect our global ambition to deliver life-transforming treatments and support better health outcomes.
Our focus is on complex and chronic conditions across our core therapeutic areas: gastroenterology, neuroscience, rare diseases and oncology.
You can learn more about our global research and therapeutic areas here.
News
Contact us
Takeda Pharmaceuticals Australia Pty Ltd
Phone
To Report Suspected Side Effects for Takeda Products
Medical Information and other inquiries for Takeda Products
Patients should always consult their doctor for medical advice.
Important Information
Reconciliation Action Plan
Takeda is dedicated to making a meaningful contribution to reconciliation and fostering a more inclusive and equitable society. Our Reflect Reconciliation Action Plan (RAP) is an outline of Takeda’s commitment to a culture of continuous learning through experience, connection, and open ears and eyes. Central to this commitment is fostering relationships, respect, and trust between employees and Aboriginal and Torres Strait Islander Peoples.
We believe that by building meaningful relationships and increasing cultural understanding, we can make meaningful contributions to reconciliation within our sphere of influence in the healthcare sector. As an organisation that delivers innovative medicines and services, we want to work towards the removal of barriers that exist in accessing these medicines, as well as the healthcare system more broadly.
Takeda's Reflect RAP is our roadmap to growing these connections and identifying how we can deliver culturally appropriate engagement and delivery of services. We hope that these steps contribute to a journey towards equitable health outcomes for all Australians.
Our RAP artwork, created by Guugu Yimithirr artist Susan Reys, symbolises the many connections between nature, health, and Takeda's vision, incorporating elements like the Wattle tree, which is important to all First Nations Cultures both spiritually and medicinally, and which ties closely to Takeda’s Cherry Blossom tree, representing our cultural heritage and history, and a sign of our solid past and continuing future.
Takeda Australia Workplace Gender Equality
At Takeda, we strive to have a workforce as diverse as the patients we serve. We are committed to embracing differences, exploring possibilities, and developing our colleagues. In January 2024, Takeda in Australia achieved Top Employer certification for the eighth consecutive year, whilst globally, Takeda achieved Top Employer certification for the seventh consecutive year, demonstrating our efforts to create an environment where our people feel valued for the contribution they make, regardless of who they are and where they come from. In 2023, 58% of Oceania leadership roles were occupied by women, reinforcing our commitment to ensuring that all employees are given the opportunities they deserve.
Our values are Integrity, Fairness, Honesty, and Perseverance and our priorities, Patient-Trust-Reputation-Business, these guide every decision we make and every action we take – it is who we are. Our success depends on fostering an inclusive environment where all colleagues are welcomed, empowered, and inspired to use their unique voices and talents. We believe this is how we’ll find innovative approaches to serve our patients, customers, and communities.
To learn more about our efforts to integrate diversity, equity, and inclusion into our company culture, please refer to our Takeda Australia Gender Pay Gap Statement published 2024.
Transparency Reporting
Takeda Pharmaceuticals Australia Pty Ltd has undertaken to be open and transparent in its interactions with the community in which it operates. As a member of Medicines Australia, we publish the details of reportable payments or transfers of value to healthcare professionals. Reportable payments or transfers of value are:
Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant; Airfares, accommodation and/or conference registration fees provided as part of services as above, or to attend medical education. Takeda Pharmaceuticals Australia Pty Ltd prepares reports for publication in accordance with the Medicines Australia Code of Conduct and Australia’s Privacy legislation. The reports for expenditure prior to 1 October 2016 identify healthcare professionals by name where their consent has been provided. Where consent has not been provided the information is reported in aggregate.
From 1 October 2016, reporting these payments is mandatory – details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name.
From 30 August 2019, the information included in the 1 November 2018 – 30 April 2019 report and all future reports will be available in a database, administered by Medicines Australia for those healthcare professionals who have been informed that this information will be published in this database. This database is designed to be searchable and can be downloaded as a CSV file.
For further information about the details in the report, or to search the database, please visit www.DisclosureAustralia.com.au
To comply with our privacy obligations, the reports may be amended from time to time. The reports here contain the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, which must comply with the Australian Privacy Act 1988.